The PennZone

  • Home
  • Health
  • Business
  • Non-profit
  • Technology
  • Travel
  • Construction
  • Medical
  • Entertainment

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
  • CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
  • Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • P-Wave Press Announces Pushing the Wave 2024 by L.A. Davenport
  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
  • "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • CollabWait to Launch Innovative Waitlist Management Platform for Behavioral Health Services
  • Urban Bush Women Celebrates Bessie Award Nominations & Winter 2026 Touring
  • Imagen Golf Launches "Precision Lessons" with Trackman iO in Newtown, PA
  • New Report Reveals Surprising Trends in Illinois Airport Accidents
  • PebblePad Acquires myday to Deliver Unified Digital Campus Experiences for Student Success
  • Adam Clermont Releases New Book – Profit Before People: When Corporations Knew It Was Dangerous and Sold It Anyway
  • Dirty Heads, 311, Tropidelic, and The Movement to Headline Everwild Music Festival in 2026 with its largest lineup to date!
  • VIP Vacations Honored by Lomas as One of Top Overall Travel Agencies
  • The Stork Foundation Announces 2025 Year-End Impact and Grant Awards Amid Rising National Demand
  • Stout Industrial Technology Appoints Paul Bonnett as Chief Executive Officer
  • Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
  • Syntax of Sorrow: An Exhibition Examining Synthetic Affliction in the Age of Artificial Intelligence
  • Waarom brand mentions in ChatGPT steeds belangrijker worden
  • Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
  • At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
  • Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
  • Insight Holistic Imaging Introduces In-LightN Advanced Thermography - New Personalized Wellness Scr
  • TrueNorth Wellness Services Welcomes a New CEO
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration

Popular on PennZone

  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 274
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 258
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 137
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • Nonprofit Operations' First-Of-Its-Kind Job Portal Empowers Nonprofit Job Seekers
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration

Similar on PennZone

  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us